Impact Factor
3.94
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.06
782 total citations
h5-index
29
h5 depth signal
Cited share
87.2%
123 of 141
Total citations
782
Citation footprint
Metric signal
5.09
External metric anchor
Self-citation
5.4%
42 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
127
France
71
Germany
66
Netherlands
66
Denmark
64
Citing Fields of Research
Endocrinology & Metabolism
666
Oncology
58
Endocrine Therapy
26
Immunology
20
Cancer & Development
13
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
985
Articles tracked across the journal lifetime
Indexed publication set
141
123 cited publications
Last 12 months
103
8.6 publications/month
Open access share
100.0%
103 OA publications in the last year
Leading citing country
Italy
127 citing publications
Leading citing field
Endocrinology & Metabolism
666 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v12n1, Feb. 2023-
v1, 2012-
Active Coverage
Research Focus & Classification
Indexed Subjects
Endocrinology & Metabolism
Issuing & Sponsoring Bodies
Contributor
European Thyroid Association
Broad Categories
Endocrinology
Neoplasms
Endocrinology & Metabolism
MeSH Descriptors
Thyroid Diseases
Thyroid Gland
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1530/etj-26-0241
Open DOI
Transcriptomics of thyroid cancer
The review of achievements in thyroid cancer (TC) transcriptomics aims to show how they have deepened our understanding of the processes underlying malignant transformation and the mechanisms of TC progression. The review starts with the...
02
DOI 10.1530/etj-26-0237
Open DOI
Management of Nondiagnostic Thyroid Fine Needle Aspiration Cytology Nodules Based on TI-RADS Risk Assessment
Objective: The high prevalence of thyroid nodules and the frequent occurrence of nondiagnostic (ND) results on fine-needle aspiration (FNA) necessitates malignancy risk stratification to balance cancer detection while avoiding unnecessar...
03
DOI 10.1530/etj-26-0128
Open DOI
TERT promoter mutations in papillary thyroid carcinoma: association with gross extrathyroidal invasion and outcomes
Context: Morbidity of papillary thyroid carcinoma (PTC) is primarily related to locoregional and distant metastases. Extrathyroidal extension (ETE) is associated with adverse outcomes; however, the biological heterogeneity across its deg...
04
DOI 10.1530/etj-26-0216
Open DOI
Intranodular Lactate for Thyroid Nodule Assessment: Universal Performance and Maximum Impact in Indeterminate Cytology
Objective: Thyroid nodules with indeterminate cytology often undergo diagnostic surgery despite a relatively low risk of malignancy, and molecular testing is limited by cost and availability. Because the Warburg effect is independent of ...
05
DOI 10.1530/etj-26-0166
Open DOI
Tipping the balance: thyroid hormones as modulators of the sensitive harmony of innate immunity
Thyroid hormones (THs) are increasingly recognized as important regulators of innate immune cell function. As innate immune cells are essential for combating infections, TH status may, therefore, be a determinant of susceptibility to dev...
06
DOI 10.1530/etj-26-0135
Open DOI
Association of TP53 Mutational Status and Survival in Anaplastic Thyroid Cancer Treated with Dabrafenib Plus Trametinib
Objective: Anaplastic thyroid cancer (ATC) is an extremely aggressive tumour, with high mortality rates. Dabrafenib plus Trametinib (DT) has significantly impacted the survival of patients with BRAF p.V600E ATC, with noticeable variation...
07
DOI 10.1530/etj-26-0144
Open DOI
Disease burden and long-term psychosocial outcomes in children and young adults with Graves’ disease
Background: Research in paediatric Graves’ disease (GD) has predominantly focused on endocrine treatment outcomes. There is limited knowledge about associations with other diseases and long-term psychosocial outcomes. Objective: We aimed...
08
DOI 10.1530/etj-26-0226
Open DOI
Calcitonin-negative ‘MTC-like’ thyroid paraganglioma revealing an SDHD -related hereditary paraganglioma syndrome: functional confirmation of a non-canonical splice-site variant
Introduction: Primary thyroid paraganglioma (TPGL) is a rare mimic of medullary thyroid carcinoma (MTC). We report an SDHD-related TPGL caused by a non-canonical splice-region variant. Case presentation: A 36-year-old woman underwent thy...
09
DOI 10.1530/etj-26-0053
Open DOI
Clinical outcomes of pembrolizumab combination therapy in heavily pretreated PDTC and anaplastic thyroid cancer
Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive malignancies with limited treatment options. Although targeted therapies for tumours harbouring BRAF V600E mutations o...
10
DOI 10.1530/etj-26-0068
Open DOI
TERT reactivation in thyroid cancer: mechanisms, clinical implications, and therapeutic opportunities
Somatic mutations in the telomerase reverse transcriptase (TERT) promoter are key molecular events in thyroid carcinogenesis and are strongly associated with aggressive clinical behaviour. The c.-124C>T and c.-146C>T hotspot mutations, d...
Bibliographical & Catalog Notes
Print issues ceased with v. 10, no. 6 (2021).
Vol. 1, no. 1 (2012) preceded by an issue called "Launching Issue 2011" and Vol. 1, suppl. 1, 2012.
Also issued online.